Treatment with lentiviral vectors encoding shRNA against interleukin 10 modulates the immunosuppressive activity of murine colon carcinoma‑associated myeloid‑derived suppressor cells

Anger‑Góra,Natalia; Węgierek‑Ciura,Katarzyna; Szczygieł,Agnieszka; Mierzejewska,Jagoda; Pajtasz‑Piasecka,Elżbieta; Rossowska,Joanna

doi:10.3892/ol.2021.12843

Treatment with lentiviral vectors encoding shRNA against interleukin 10 modulates the immunosuppressive activity of murine colon carcinoma‑associated myeloid‑derived suppressor cells

Authors:
- Natalia Anger‑Góra
- Katarzyna Węgierek‑Ciura
- Agnieszka Szczygieł
- Jagoda Mierzejewska
- Elżbieta Pajtasz‑Piasecka
- Joanna Rossowska
View Affiliations

Affiliations: Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53‑114 Wrocław, Poland
Published online on: June 2, 2021 https://doi.org/10.3892/ol.2021.12843
Article Number: 582
Copyright: © Anger‑Góra et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myeloid‑derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and their accumulation is often associated with poor prognosis. The aim of the present study was to determine the mechanisms of action of lentiviral vectors encoding short hairpin (sh)RNA against interleukin‑10 (IL‑10), with particular emphasis on their influence on the activity of tumor‑derived MDSCs. Lentiviral vectors encoding shRNA against IL‑10 (shIL‑10 LVs) were utilized to silence the expression of IL‑10 either in MDSCs that were generated ex vivo from bone marrow cells cultured in the presence of supernatant from MC38 colon carcinoma cells, or in situ in the MC38 murine colon carcinoma environment. Although monocytic MDSCs (M‑MDSCs) transduced with shIL‑10 LVs exhibited increased suppressor activity, transduction of polymorphonuclear MDSCs (PMN‑MDSCs) appeared to reduce their ability to inhibit T lymphocyte functions. Analysis of EGFP expression in MC38 tumors revealed that intratumorally inoculated shIL‑10 LVs transduced tumor‑infiltrating myeloid cells with the highest efficiency and, led to a decreased IL‑10 level in the tumor microenvironment. However, the effect was accompanied by increased influx of PMN‑MDSCs into tumors observed both on the 6th and on the 10th day after shIL‑10 LV injections. Nevertheless, it was noted that suppressor activity of myeloid cells isolated from tumors was dependent on the efficiency of tumor‑derived PMN‑MDSC transduction with shIL‑10 LVs. The increased percentage of transduced PMN‑MDSCs on the 10th day was associated with diminished immunosuppressive activity of tumor‑derived myeloid cells and an elevated ratio of cytotoxic T lymphocytes to M‑MDSCs. The obtained data indicated that treatment with shIL‑10 LVs may result in modulation of the immunosuppressive activity of MC38 colon carcinoma‑derived MDSCs.

View Figures

View References

1	Buoncervello M, Gabriele L and Toschi E: The janus face of tumor microenvironment targeted by immunotherapy. Int J Mol Sci. 20:43202019. View Article : Google Scholar : PubMed/NCBI
2	Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment: Removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 27:1482–1492. 2016. View Article : Google Scholar : PubMed/NCBI
3	Kumar V, Patel S, Tcyganov E and Gabrilovich DI: The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37:208–220. 2016. View Article : Google Scholar : PubMed/NCBI
4	Marvel D and Gabrilovich DI: Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest. 125:3356–3364. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, et al: Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 5:442017. View Article : Google Scholar : PubMed/NCBI
6	Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL and Mehnert JM: Biomarkers for immunotherapy: Current developments and challenges. Am Soc Clin Oncol Educ Book. 35:e493–e503. 2016. View Article : Google Scholar : PubMed/NCBI
7	Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, et al: Validation of biomarkers to predict response to immunotherapy in cancer: Volume I-pre-analytical and analytical validation. J Immunother Cancer. 4:762016. View Article : Google Scholar : PubMed/NCBI
8	Anger N and Rossowska J: Myeloid-derived suppressor cells as a target for anticancer therapy. Postępy Higieny i Medycyny Doświadczalnej. 72:1179–1198. 2018. View Article : Google Scholar
9	Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, Zhang Z, Dietz AB, Porrata LF, Novak AJ, et al: IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J. 5:e3282015. View Article : Google Scholar : PubMed/NCBI
10	Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S and Wei H: Ascites-derived IL-6 and IL-10 synergistically expand CD14⁺HLA-DR^−/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 8:76843–76856. 2017. View Article : Google Scholar : PubMed/NCBI
11	Steinbrink K, Wölfl M, Jonuleit H, Knop J and Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 159:4772–4780. 1997.PubMed/NCBI
12	Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C and Girolomoni G: Human CD4⁺ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol. 114:295–302. 2000. View Article : Google Scholar : PubMed/NCBI
13	Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J and Mantovani A: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 164:762–767. 2000. View Article : Google Scholar : PubMed/NCBI
14	Dennis KL, Blatner NR, Gounari F and Khazaie K: Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol. 25:637–645. 2013. View Article : Google Scholar : PubMed/NCBI
15	Fiorentino DF, Bond MW and Mosmann TR: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 170:2081–2095. 1989. View Article : Google Scholar : PubMed/NCBI
16	Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ and Selvan SR: Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy. Immunol Res. 51:170–182. 2011. View Article : Google Scholar : PubMed/NCBI
17	Rossowska J, Anger N, Szczygieł A, Mierzejewska J and Pajtasz-Piasecka E: Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy. J Exp Clin Cancer Res. 37:1262018. View Article : Google Scholar : PubMed/NCBI
18	Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E and Zitvogel L: Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 33:369–383. 2011. View Article : Google Scholar : PubMed/NCBI
19	Pajtasz-Piasecka E, Szyda A, Rossowska J, Krawczenko A, Indrová M, Grabarczyk P, Wysocki P, Mackiewicz A and Duś D: Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha). 50:7–14. 2004.PubMed/NCBI
20	Rossowska J, Pajtasz-Piasecka E, Anger N, Wojas-Turek J, Kicielińska J, Piasecki E and Duś D: Cyclophosphamide and IL-12-transduced DCs enhance the antitumor activity of tumor antigen-stimulated DCs and reduce Tregs and MDSCs number. J Immunother. 37:427–439. 2014. View Article : Google Scholar : PubMed/NCBI
21	Rossowska J, Anger N, Szczygieł A, Mierzejewska J and Pajtasz-Piasecka E: Intratumoral lentivector-mediated TGF-β1 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells. Front Immunol. 8:7132017. View Article : Google Scholar : PubMed/NCBI
22	Breckpot K, Escors D, Arce F, Lopes L, Karwacz K, Van Lint S, Keyaerts M and Collins M: HIV-1 Lentiviral vector immunogenicity is mediated by toll-like receptor 3 (TLR3) and TLR7. J Virol. 84:5627–5636. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G and Zou W: Interleukin (IL)-10 ablation promotes tumor development, growth and metastasis. Cancer Res. 72:420–429. 2012. View Article : Google Scholar : PubMed/NCBI
24	Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014. View Article : Google Scholar : PubMed/NCBI
25	Breckpot K, Emeagi PU and Thielemans K: Lentiviral vectors for anti-tumor immunotherapy. Curr Gene Ther. 8:438–448. 2008. View Article : Google Scholar : PubMed/NCBI
26	Furmanov K, Elnekave M, Lehmann D, Clausen BE, Kotton DN and Hovav AH: The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. J Immunol. 184:4889–4897. 2010. View Article : Google Scholar : PubMed/NCBI
27	Olbrich H, Slabik C and Stripecke R: Reconstructing the immune system with lentiviral vectors. Virus Genes. 53:723–732. 2017. View Article : Google Scholar : PubMed/NCBI
28	Milone MC and O'Doherty U: Clinical use of lentiviral vectors. Leukemia. 32:1529–1541. 2018. View Article : Google Scholar : PubMed/NCBI
29	Nash AA and Dutia BM: The Immune response to viral infections. Topley & Wilson's Microbiology and Microbial Infections. American Cancer Society, . 15–Mar;2010.doi: 10.1002/9780470688618.taw0220. View Article : Google Scholar
30	Tan Z, Liu L, Chiu MS, Cheung KW, Yan CW, Yu Z, Lee BK, Liu W, Man K and Chen Z: Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression. Oncoimmunology. 8:e15186722019. View Article : Google Scholar : PubMed/NCBI
31	Rossowska J, Anger N, Kicielińska J, Pajtasz-Piasecka E, Bielawska-Pohl A, Wojas-Turek J and Duś D: Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology. 220:389–398. 2015. View Article : Google Scholar : PubMed/NCBI
32	Abu Eid R, Razavi GSE, Mkrtichyan M, Janik J and Khleif SN: Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res. 4:377–382. 2016. View Article : Google Scholar : PubMed/NCBI
33	Huang XM, Zhang NR, Lin XT, Zhu CY, Zou YF, Wu XJ, He XS, He XW, Wan YL and Lan P: Antitumor immunity of low-dose cyclophosphamide: Changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis. Gastroenterol Rep (Oxf). 8:56–65. 2019. View Article : Google Scholar : PubMed/NCBI
34	Matar P, Rozados VR, Gervasoni SI and Scharovsky OG: Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol. 1:307–319. 2001. View Article : Google Scholar : PubMed/NCBI
35	Xia Q, Geng F, Zhang FF, Liu CL, Xu P, Lu ZZ, Zhang HH, Kong W and Yu XH: Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 34:4526–4535. 2016. View Article : Google Scholar : PubMed/NCBI
36	Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L and Garg AD: Trial watch: Chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 9:17034492020. View Article : Google Scholar : PubMed/NCBI
37	Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al: Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71:768–778. 2011. View Article : Google Scholar : PubMed/NCBI
38	Mikyšková R, Indrová M, Vlková V, Bieblová J, Šímová J, Paračková Z, Pajtasz-Piasecka E, Rossowska J and Reiniš M: DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. 95:743–753. 2014. View Article : Google Scholar
39	Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M and Umansky V: Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol. 133:1610–1619. 2013. View Article : Google Scholar : PubMed/NCBI